UNLOCKING WHAT CANCER IS HIDING
Telomir Pharmaceuticals is a clinical-stage company developing an oral small molecule for triple-negative breast cancer, targeting the iron-dependent epigenetic mechanisms that drive tumor survival.
Telomir-Zn is advancing toward clinical evaluation in triple-negative breast cancer (TNBC), an area of significant unmet medical need.
Latest News
Email Alerts
& get notified, as they happen